<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-814
Date of Submission: 2025-04-30

This report was submitted by a Other Healthcare Professional from Munoz-Martin Medical Center concerning patient ANON-PX-4929. The subject is a 68-year-old female with a significant medical history including seasonal allergies, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Oral route at a dosage of 172mg, initiated on 2025-03-10 for Hypercholesterolemia and discontinued on 2025-04-12; Lisinopril (ACE inhibitor) administered via the Intravenous route at a dosage of 271mg, initiated on 2025-03-10 for Hypertension and discontinued on 2025-04-12.

On approximately 2025-03-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Dizziness. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed people and advised score. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed Congress and advised us. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: East dark wide. Wear exactly myself company each. Pick rise space develop artist.</data>
report_id: ADR-2025-814
report_date: '2025-04-30'
patient_details:
  patient_id: ANON-PX-4929
  gender: Female
  relevant_history:
  - seasonal allergies
  - atrial fibrillation
  age_at_reaction: 68
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 172mg
  route_of_administration: Oral
  start_date: '2025-03-10'
  indication_for_use: Hypercholesterolemia
  end_date: '2025-04-12'
- drug_name: Lisinopril
  dosage: 271mg
  route_of_administration: Intravenous
  start_date: '2025-03-10'
  indication_for_use: Hypertension
  drug_class: ACE inhibitor
  end_date: '2025-04-12'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-03-21'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed people and advised score.
- symptom_name: Dizziness
  onset_date: '2025-03-21'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed Congress and advised us.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
reporting_facility: Munoz-Martin Medical Center
reporter_type: Other Healthcare Professional
notes: East dark wide. Wear exactly myself company each. Pick rise space develop artist.
